Nuvilex Is Ready to Lead the Medical Marijuana Research Arena

BALTIMORE, MD--(Marketwired - Jul 29, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes in a recent article on its website that Nuvilex Inc.'s ( OTCQB : NVLX ) recent acquisition of all of the oncology-related assets and licenses for the use of a live-cell encapsulation therapy serves as a catalyst to accelerate the research engaged by its subsidiary, Medical Marijuana Sciences, Inc.

With exclusive worldwide rights in the entire oncology space, and with broad access to encapsulated live cells, management may elect to study the effects of multiple cannabidiol (CBD)-based cancer treatments. These studies would seek to combine the Company's highly efficacious live-cell encapsulation-based therapies used for oncology therapy, with therapies based on cannabidiol. CBD is one of about 70 constituents of Cannabis that are collectively known as cannabinoids. The medical marijuana arena is enjoying a great deal of attention and a growing cadre of investors and entrepreneurs as many prognosticators forecast huge revenue growth over the next 3 years as more states pass medical marijuana legislation. For example, independent financial news and data firm See Change Strategy estimates that the U.S. medical marijuana market is worth $1.7 billion and could reach $8.9 billion by 2016.

In a landmark announcement in mid-July of this year, a large-scale medical marijuana research study was just commissioned by the National Institutes of Health. This is significant due to the negative approach the federal government has previously taken towards medical marijuana. Observers may view this news as a potential softening of its position on marijuana which still classifies it as a Schedule I controlled substance.

According to Drexel University's website, Drexel has received a grant for a five-year study of medical marijuana and its impact on drug use and physical and psychological health among young adults in Los Angeles. It is the first large-scale NIH project funded to directly investigate medical marijuana use among young adults aged 18 to 26.

If these kinds of dollars are going to be provided by NIH, Nuvilex appears well positioned to be eligible to receive research lucrative grants or funding from other partner firms seeking to study the efficacy of live-cell encapsulation-based therapies used for oncology therapy, with those based on cannabidiol or other cannabinoids. Given that virtually no other firm in the space can match its clinical trials and oncology R&D experience, Nuvilex is primed to be a high-profile, go-to medical marijuana research force. 

To view Nuvilex reports and articles and to view our disclaimer, please visit

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Nuvilex, Inc. ( OTCQB : NVLX ): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product-based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information, visit